# MANAGEMENT OF EARLY HYPOTHYROIDISM (QILLAT-I-DARQIYYAT) WITH A UNANI REGIMEN: A CASE REPORT

# Adnan Ali<sup>1</sup>, Mohammed Sheeraz Mushtaque Ahmed<sup>2</sup>\* and Humera Zaki<sup>3</sup>

<sup>1</sup>PG Scholar (M.D), Department of *Moalajāt*, Regional Research Institute of Unani Medicine, University of Kashmir, Habak, Naseembagh Campus, Hazratbal, Jammu and Kashmir, India <sup>2\*</sup>Research Officer Level II & Reader, Department of *Moalajāt*, Regional Research Institute of Unani Medicine, University of Kashmir, Habak, Naseembagh Campus, Hazratbal, Jammu and Kashmir, India <sup>3</sup>PG Scholar (M.D), Department of *Mahiyatul Amraz*, National Institute of Unani Medicine, Rajiv Gandhi University of Health Sciences, Bengaluru, Karnataka, India

## Review Paper

Received: 16.07.2025 Revised: 00.00.2025 Accepted: 00.00.2025

## **ABSTRACT**

*Background:* Hypothyroidism is a prevalent endocrine disorder characterized by insufficient thyroid hormone production, leading to various systemic effects such as fatigue, indigestion, mood disturbances, and metabolic slowing. While conventional treatment includes hormone replacement therapy, Unani medicine offers alternative approaches. Hypothyroidism symptoms align closely with those of "Su-e-Mizaj Barid Maddi" in Unani texts, indicating potential for traditional interventions.

**Objectives:** To evaluate the effectiveness and safety of a Unani regimen comprising *Sufoof-e-Hazim*, *Arq Badiyan*, and *Hab Kabid Naushadri* in managing early hypothyroidism symptoms and improving thyroid function.

*Methods:* A 60-year-old male with symptoms of indigestion, disturbed sleep, and generalized weakness was treated at the Regional Research Institute of Unani Medicine, Srinagar. Diagnostic investigations confirmed early hypothyroidism (TSH: 9.7  $\mu$ IU/mL). A 60-day Unani treatment regimen was administered with biweekly follow-ups assessing clinical symptoms, vitals, and therapy tolerance. Thyroid function was re-evaluated at the end of the treatment.

**Result:** The patient showed significant clinical improvement, including better digestion, sleep quality, and energy levels. Follow-up Thyroid Function Test revealed a reduction in TSH to 3.6  $\mu$ IU/mL, suggesting endocrine improvement. No adverse effects were observed, supporting the regimen's efficacy and safety in managing early hypothyroidism through Unani medicine.

No. of Pages: 6 No. ot Tables: 3 No. of Figures: 1 References: 37

**Keywords:** Hypothyroidism, Unani Medicine, Su-e-Mizaj Barid Maddi, Thyroid Function Test, Qillat-e-Ifraz-e-Darqiya.

## 1. Introduction

Hypothyroidism, a common thyroid hormone deficiency, can cause serious health issues and death if untreated. Diagnosis relies on biochemical markers due to varied, non-specific symptoms.[1] It results from genetic abnormalities, gland removal, destruction, or autoimmune damage, leading to

reduced hormone signaling and affecting mood, cognition, and metabolism.[2] Clinical presentations range from severe myxedema to asymptomatic/subclinical forms with mildly elevated thyrotropin levels, affecting 4-15% of developed countries' populations.[3] Overall prevalence is 3.8-4.6%, with women more affected. Conventional treatment

<sup>\*</sup>Corresponding author: drsheerazmd@gmail.com

involves hormone replacement therapy. [4-9] In Unani medicine, "Qillat-e-Ifraz-e-Darqiyya" describes hypothyroidism, caused by thyroid gland abnormalities and reduced hormone production. [10]

Hypothyroidism has diverse causes and symptoms. [11] Untreated or chronic hypothyroidism can lead to co-morbidities like anemia, hypertension, hypercholesterolemia, diabetes, obesity, myopathy, migraine, depression, and anxiety. [12] While not directly described in Unani medicine, symptoms of "Su-e-Mizaj Barid Balghami" (disturbed phlegmatic temperament) in Unani literature are similar to modern hypothyroidism symptoms. [13-16]

Unani physicians, including Hippocrates, Galen, Zakaria Razi (865–925 AD), Ali Ibn-e-Abbas Majoosi (983 AD), Ibn-e-Sina (980-1037 AD), Ismail Jurjani (1040-1136 AD), Ibn-e-Hubal Baghdadi (1121-1213 AD), Ibn-e-Rushd (1126-1128 AD), and Ibn-e-Zohr (1094-1162), recognized glands and related pathologies.[17-18] Unani philosophy links health and illness to humoral and temperamental balance. Diseases arise from imbalances in humors or temperament, influenced by various factors.[19] "Su-e-Mizaj Barid" (cold temperament) occurs with cold organ imbalances, showing signs like excessive sleep, appetite loss, and pale skin. Hypothyroidism symptoms resemble "Su-e-Mizaj Barid Maddi," including plethoric appearance, salivation, fatigue, appetite loss, sleepiness, and cold skin, attributed to abnormal

phlegm excess.[20] Clinical manifestations of "Su-e-Mizaj Barid Maddi," detailed by Unani scholars, align with hypothyroidism symptoms.[21-32]

## MATERIAL AND METHODS

The study was conducted in 2025 at the Regional Research Institute of Unani Medicine, Srinagar, affiliated with the University of Kashmir. Results were published while maintaining patient confidentiality in line with prior consent. The patient was treated with a combination of Sufoof-e-Hazim, Arq Badiyan, and Hab Kabid Naushadri, each prescribed with specific dosages and therapeutic intentions.

#### **Case History**

A 60-year-old male presented to the Regional Research Institute of Unani Medicine, Srinagar, University of Kashmir, with complaints of indigestion, hyperacidity, disturbed sleep, and generalized weakness for the past several months. He reported persistent indigestion with a sensation of fullness after meals, frequent belching, and bloating, along with hyperacidity, particularly after consuming spicy or heavy foods. The patient also experienced difficulty sleeping, marked by frequent nighttime awakenings, and complained of generalized weakness and morning fatigue. Occasionally, he experienced mild headaches without associated nausea or photophobia. There was no history of diabetes, hypertension, cardiac illness, or gastrointestinal ulcers. He was not on any regular medication prior to the onset of symptoms and denied any history of substance use.

Table 1: Laboratory Investigations.

Test	Result	Interpretation
TSH	$9.7~\mu IU/mL$	Elevated
Free T3, Free T4	Low-normal	Suggestive of early hypothyroidism
Complete Blood Count (CBC)	Within normal limits	
Fasting & Random Blood Sugar	Normal	
LFT/KFT	Normal	
ECG	Normal sinus rhythm	

As shown in Table 1, the laboratory investigations revealed a significantly elevated TSH level (9.7  $\mu$ IU/mL) with low-normal Free T3 and T4, which is suggestive of early hypothyroidism. Other routine investigations including CBC, blood sugar levels, liver

and kidney function tests, and ECG were within normal limits, indicating no systemic illness or metabolic disturbance apart from thyroid dysfunction.

Table 2: Clinical Examination Findings.

Parameter	Findings	
General Appearance	Mildly pale, no icterus or edema	
Vitals	BP: 122/78 mmHg, Pulse: 74 bpm, Afebrile	
Weight	Slightly increased, no recent loss	
Abdominal Examination	Mild epigastric tenderness, no organomegaly	
Neurological Exam	Normal, no focal deficits	
Cardiovascular System	Normal heart sounds, no murmurs	
Respiratory System	Clear breath sounds	
Sleep Assessment	Difficulty initiating sleep, frequent nighttime waking	
Mental State	Mild lethargy, no signs of depression	

Table 2 Highlights the findings from the clinical examination. The patient appeared mildly pale, but there were no signs of edema, jaundice, or acute systemic involvement. His vitals were stable, and both cardiovascular and respiratory examinations were unremarkable. Notably, sleep assessment indicated insomnia with frequent nighttime awakenings,

aligning with his complaints of disturbed sleep. Mental and neurological assessments were within normal limits, excluding any neuropsychiatric contribution to his symptoms.

## Therapeutic intervention

Prescribed Unani Combination Therapy (Duration: 60 Days)

Table 2: Clinical Examination Findings.

	The state of the s					
Medicine	Formulation Type	Dosage	Purpose / Therapeutic Actions	Reference		
Sufoof-e- Hazim	Polyherbal powder	5 grams twice daily after meals	Improves digestion - Relieves flatulence and bloating - Acts as an appetizer	[33]		
Arq Badiyan	Herbal distillate	30 ml twice daily after meals	Digestive, gastroprotective, hepatoprotective - Antispasmodic and carminative - Diuretic and anorectic-Effective in fatty liver, improves HDL	[34]		
Hab Kabid	tablet/pill	2 tablets	Supports liver function - Promotes overall	[34]		
Naushadri		twice daily with lukewarm water	digestive wellness			

#### Follow up and outcome measures

The therapy was followed for a duration of 60 days, with follow-ups conducted at regular intervals every 15 days to monitor the patient's clinical progress. Throughout the treatment period, the patient demonstrated steady improvement in symptoms without any adverse effects such as indigestion, nausea, or other complications, confirming the safety and tolerability of the prescribed Unani regimen. At each follow-up, the patient's vitals were recorded, and

regular monitoring of the thyroid function was recommended to assess the therapeutic effectiveness. At the end of the 60-day treatment period, a repeat Thyroid Function Test (TFT) was performed, which showed improvement in thyroid levels, indicating a positive response to the treatment.

## **RESULTS**

Reported marked clinical improvement. Symptoms of indigestion, hyperacidity, disturbed sleep, and

generalized weakness had notably subsided. The patient experienced better sleep quality, improved digestion, and increased overall energy levels.

A repeat Thyroid Function Test (TFT) conducted on the 60th day revealed a significant reduction in TSH levels from 9.7  $\mu$ IU/mL to 3.6  $\mu$ IU/mL, bringing it closer to the normal reference range. Free T3 and Free

T4 levels remained within low-normal limits, indicating a favorable endocrine response. No adverse effects or complications were reported throughout the treatment period, and vital signs remained stable across all follow-ups. These findings suggest that the combination therapy was both effective and well-tolerated, contributing positively to both digestive wellness and thyroid function regulation (Chart 1).




Chart 1: Showing the significant reduction in TSH levels from 9.7  $\mu$ IU/mL before treatment to 3.6  $\mu$ IU/mL after 60 days of Unani therapy.

#### **DISCUSSION**

This case underscores the therapeutic potential and safety of a classical Unani regimen—Sufoof-e-Hazim, Arg Badiyan, and Hab Kabid Naushadri—in the management of early hypothyroidism accompanied by digestive disturbances. The patient exhibited notable symptomatic improvement and a marked reduction in TSH levels from 9.7 μIU/mL to 3.6  $\mu$ IU/mL within 60 days, without any adverse effects. The clinical benefits observed may be due to the synergistic action of the formulations, each grounded in Unani principles. Sufoof-e-Hazim, mentioned in Al-Qanoon fi'l-Tibb and Makhzan al-Adwiyah, functions as a Hazim (digestive) and Muqawwi-i-Meda (stomach tonic), promoting gastric function and relieving dyspepsia. Arq Badiyan, described in Bayaze-Kabir and Qarabadin-e-Azam, acts as a Mufttih (deobstruent) and Mufarrih (exhilarant), relieving bloating and digestive distress, and may exert mild Moaddil-i-Hormonal effects, Hab Kabid Naushadri, a well-known liver tonic in Unani medicine, supports hepatic detoxification and T4 to T3 conversion, crucial for thyroid function. By addressing Asbab such as Su-e-Hadm, Zo'f-i-Kabid, and Imtila, this regimen reflects the holistic approach of Unani medicine in restoring metabolic and hormonal balance, meriting further scientific evaluation.

#### **CONCLUSION**

The case highlights the potential benefits of Unani medicine in the management of early hypothyroidism accompanied by digestive disturbances. The combination therapy of Sufoof-e-Hazim, Arq Badiyan, and Hab Kabid Naushadri was effective in relieving symptoms such as indigestion, hyperacidity, disturbed sleep, and generalized weakness, while also significantly reducing TSH levels from 9.7 to 3.6  $\mu$ IU/mL. The treatment was well-tolerated, with no reported side effects during the 60-day duration. These findings suggest that traditional Unani formulations may offer a safe, holistic, and effective approach to support thyroid health and improve quality of life in patients with subclinical or early-stage hypothyroidism.

#### **Future Suggestions**

Further research with larger sample sizes and longer follow-up periods is recommended to validate these findings. Controlled clinical trials comparing Unani therapy with conventional treatments could provide stronger evidence for its efficacy and safety. Additionally, exploring the pharmacological actions of individual Unani ingredients may help understand their role in thyroid regulation and digestive support.

## Declaration of patient consent

The authors affirm that duly executed patient consent forms, authorizing the dissemination of clinical data within this publication, have been obtained. While meticulous measures will be employed to safeguard patient confidentiality, absolute anonymity cannot be assured. The patient acknowledges that their full names and initials will be withheld.

#### ACKNOWLEDGEMENT

The authors express their sincere gratitude to Dr. Irfat Ara, Deputy Director of the Regional Research Institute of Unani Medicine, Srinagar, and to the Library staff for their invaluable support and for providing extensive literature that greatly aided in the preparation of this case report.

### **Conflict of Interest**

None

#### REFERENCES

- Alam, M.A., Quamri, M.A. and Sofi, G., 2019. Understanding hypothyroidism in Unani medicine. *Journal of Herbal Medicine*, 17, pp.100292. Available at: [https://pmc.ncbi.nlm. nih.gov/articles/PMC6619426/]
- Sofian, A.A. and Sofi, G., 2024. A review on thyroid disorders in Unani Medicine. *Journal of Herbal Medicine*. 43, p.100843. Available at: [https://pmc.ncbi.nlm.nih.gov/articles/PMC1084 3736/]
- 3. Rakhshani, N. and Mobasher, B., 2013. Unani (Traditional Persian) Medicine and Hypertension. *Iranian Red Crescent Medical Journal*, 15(7), pp.558-560. Available at: [https://pmc.ncbi.nlm.nih.gov/articles/PMC3743 364/]
- 4. Mithal, A., Dharmalingam, M. and Tewari, N., 2014. Are patients with primary hypothyroidism in India receiving appropriate hyroxine replacement? An observational study. *Indian Journal of Endocrinology and Metabolism*, 18(1), pp.83–8.

- 5. **Javed, Z. and Sathyapalan, T.**, 2016. Levothyroxine treatment of mild subclinical hypothyroidism: a review of potential risks and benefits. *Therapeutic Advances in Endocrinology and Metabolism*, 7(1), pp.12–23.
- 6. **Ko**, Y.J., Kim, J.Y., Lee, J., Song, H.J., Kim, J.Y., Choi, N.K., et al., 2014. Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women. *Journal of Preventive Medicine and Public Health*. 47(1), pp.36–46.
- 7. McAninch, E.A. and Bianco, A.C., 2016. The history and future of treatment of hypothyroidism. *Annals of Internal Medicine*, 164(1), pp.50-6.
- 8. **Saifi, N., Jamal, Y. and Ram, Y.,** 2017. Correlation of thyroid hormones and Mizaj: a review. *International Journal of Physiology, Nutrition and Physical Education*, 2(2), pp.1072–4.
- 9. **Hennessey, J.V. and Espaillat, R.,** 2018. Current evidence for the treatment of hypothyroidism with levothyroxine/levotriiodothyronine combination therapy versus levothyroxine monotherapy. *International Journal of Clinical Practice*. 72(2), p.e13062.
- 10. **Chakera, A.J., Pearce, S.H. and Vaidya, B.,** 2012. Treatment for primary hypothyroidism: current approaches and future possibilities. *Drug Design, Development and Therapy*, 6, pp.1–11.
- 11. **Persani, L. and Bonomi, M.,** 2017. The multiple genetic causes of central hypothyroidism. *Best Practice & Research Clinical Endocrinology & Metabolism.* 31(2), pp.255–63.
- 12. **Klein, I. and Danzi, S.,** 2007. Thyroid disease and the heart. *Circulation*, 116(15), pp.1725–35.
- 13. **Wang, C.,** 2013. The relationship between type 2 diabetes mellitus and related thyroid diseases. *Journal of Diabetes Research.* 2013, p.390534.
- 14. **Longhi, S. and Radetti, G.,** 2013. Thyroid function and obesity. *Journal of Clinical Research in Pediatric Endocrinology*. 5(1), pp.40–4.
- 15. **Lisotto, C., Mainardi, F., Maggioni, F. and Zanchin, G.,** 2013. The comorbidity between migraine and hypothyroidism. *The Journal of Headache and Pain*, 14(Suppl 1), p.P138.
- 16. **Kamble**, **M.T.**, **Nandedkar**, **P.D.**, **Dharme**, **P.V.**, **LLS and Bhosale**, **P.G.**, 2013. Thyroid function and mental disorders: an insight into the complex interaction. *Journal of Clinical and Diagnostic Research*, 7(1), pp.11–4.

- 17. **Saifi, N., Jamal, Y. and Ram, Y.**, 2017. Correlation of thyroid hormones and Mizaj: a review. *International Journal of Physiology, Nutrition and Physical Education*, 2(2), pp.1072–4.
- 18. **Rafiuddin, Y.,** 2011. Study of Qillat-e-Ifraz-e-Darqiyya Ibtidai (primary hypothyroidism) and therapeutic evaluation of Unani formulation in its management. PhD thesis. Rajiv Gandhi University of Health Science, Bangalore.
- Ahmed, S.I., 2009. Introduction to Al-Umur-Al-Tabi'Yah. New Delhi: Central Council for Research in Unani Medicine, Ministry of Health & Family Welfare, Government of India, pp.5–136.
- 20. **Majoosi**, **A.I.A.**, 2010. Kamil Us-Sana. New Delhi: CCRUM, pp.50–5,109–16.
- 21. **Baghdadi, I.H.**, 2004. Kitab Al Mukhtaratfit-Tibb. Vol.3. New Delhi: Central Council for Research in Unani Medicine, Ministry of Health & Family Welfare, Government of India, pp.326–8.
- 22. **Sina, S.I.,** 2010. Al-Qanoon Fil-Tib. Vol-I. New Delhi: Idara Kitab-us-Shifa, pp.26–35.
- 23. **Ahmed, A.M. and Ahmed, N.H.,** 2005. History of disorders of thyroid dysfunction. *Eastern Mediterranean Health Journal*, 11(3), pp.459–69.
- 24. **Jurjani, I.**, 2010. Zakheera Khwarzm Shahi. New Delhi: Idara Kitab-us-Shifa, pp.17–29.
- 25. **Ljunggren**, **J.G.**, 1983. Who was the man behind the syndrome: Ismailal-Jurjani, Testa, Flagani, Parry, Graves or Basedow, 80(32–33), p.2902.
- 26. **Azizi, F.**, 2016. Endocrinology is fascinating. *International Journal of Endocrinology and Metabolism*, 14(4), p.e42228.

- 27. Asthiyani, S.C., Zarei, A. and Elahipour, M., 2009. Innovations and discoveries of Jorjani in medicine. *Journal of Medical Ethics and History of Medicine*, 2, p.16.
- 28. **Qamari**, **A.M.H.**, 2008. Ghina Muna (Urdu translation Minhaj ul Ilaj). New Delhi: CCRUM, pp.385–6.
- 29. **Zahrawi**, **A.Q.**, 2012. Jarahiyate-Zahrawia (Kitab Al-Tasreef). New Delhi: CCRUM, pp.85–6.
- 30. **Hannan**, A., 2001. La Qanati Rasilat Aur Atibbae Qadeem. Jahane Tib, 3(2), pp.56–60.
- 31. **Nabipour, I.**, 2003. Clinical endocrinology in the Islamic civilization in Iran. *International Journal of Endocrinology and Metabolism*, 1, pp.43–5.
- 32. Sofian, A.A. and Sofi, G., 2023. Unani Perspective on Thyroid Disorders: A Comprehensive Review. Journalof Herbal Medicine, 100843.
- 33. **Ibn Sina**. *Al-Qanoon fi'l-Tibb (The Canon of Medicine)*. Trans. Kantoori GH. New Delhi: Idara Kitab-us-Shifa; Reprint edition.
- 34. **Najmul Ghani H.** *Makhzan al-Adwiyah*. New Delhi: Idara Kitab-us-Shifa; 2010.
- 35. **Anonymous**. *Bayaz-e-Kabir*. New Delhi: CCRUM, Ministry of AYUSH, Govt. of India; Reprint edition.
- Anonymous. Qarabadin-e-Azam. New Delhi: CCRUM, Ministry of AYUSH, Govt. of India; 2006.
- 37. **Azam Khan**. *Tibb-e-Akbar*. Lucknow: Munshi Naval Kishore; Reprint edition